Andrew A. Dahl
President / Chief Executive Officer
Mr. Dahl was formerly a principal consultant and managing director of Great Northern & Reserve Partners, LLC, a marketing strategy and business planning consultancy focused on the biomed and biotech sectors, since 2005. For the previous 20 years, Mr. Dahl served as President of Dawber & Company, Inc., one of the largest independent marketing & consulting firms in the Midwest, with an extensive Fortune 500 client roster that included GM, Ford, Northwest, Xerox, AT&T and Compuware, among others. He attended the College for Creative Studies and Wayne State University. Mr. Dahl holds three US patents for interactive multimedia and is a named inventor in one recent biotech patent and several biomed patent applications.
Philip M. Rice, II
Chairman of the Board & Chief Financial Officer
Philip Rice operates a financial consultancy under the aegis of Legacy Results, LLC. Prior to 2001, he served as COO and director of Stahl’s Inc. ($90 million multi-national company), CFO of Gallagher-Kaiser Corp. ($110 million 1999 revenues) and President/CFO of Speedy International, Inc., an international print franchisor. Mr. Rice began his professional career at Deloitte & Touche where he became a Certified Public Accountant in 1979 working on international assignments. He is a member of the Michigan Association of CPAs and the American Institute of CPAs, as well as having served on the Board of Directors of the Detroit Regional Chamber of Commerce. Mr. Rice earned a Bachelor of Business Administration from the University of Cincinnati.
Dr. Amy Steffek
Medical Director, Research & Development
Amy Elizabeth Steffek, Ph.D., serves as the Company’s Director of Research & Development. She earned a Ph.D. in Neuroscience from the University of Michigan in 2007 and completed fellowships in Translational Medicine and Neuroendocrinology at the University of Michigan in 2010. Dr. Steffek has over 13 years of scientific research experience spanning neurology, cardiology, oncology, psychiatry, and endocrinology. As a consultant, she has helped companies develop pharmaceutical products, medical devices, medical IT products, and pre-clinical research services.
Adam V. Chiasson
Vice President, Operations
Mr. Chiasson brings more than 15 years of experience, primarily focused in Operations and Supply Chain. Most recent roles include President and CEO of DMAX Consulting, LLC, a strategy consultancy focused primarily on growth stage companies and Adjunct Lecturer of Supply Chain at Eastern Michigan University, specializing in Operations Planning and Supply Chain. Previously, Mr. Chiasson served in various leadership roles including Site Leader for Accuri Cytometers Inc. ($205M acquisition in 2011 by BD Bioscience) Prior to BD/Accuri, Chiasson was employed by Stirling Energy Systems, Visteon Corporation, and PepsiCo. He earned a BS from Michigan State University and MBA from Eastern Michigan University.
William P. Pfund
Vice-President of Research & Development
Mr. Pfund brings more than 30 years of technical and operational leadership experience in FDA-regulated companies to his role as Vice-President, Research & Development at ZIVO Bioscience, Inc., including more than 18 years at Pfizer (legacy Upjohn) where he held numerous positions spanning the entire drug discovery and development continuum. He brings a wealth of technical expertise, process control and managerial experience to the Company that will help drive value. Following his tenure at Pfizer, Mr. Pfund served as the Vice President, Product Development for RealBio Technology, Inc., an emerging research tools company, and held Director-level positions at several leading contract research organizations including Eurofins, Covance and NAMSA. Mr. Pfund earned a B.S. (Biology) from the State University of New York, College at Oswego, and a M.S. (Microbiology) from The Ohio State University.